Welcome to our dedicated page for Gain Therapeutics SEC filings (Ticker: GANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gain Therapeutics, Inc. (GANX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company and an emerging growth company, Gain Therapeutics uses SEC reports to provide detailed information on its business, financial condition and progress in developing allosteric small molecule therapies such as GT-02287 for Parkinson’s disease.
Through this page, readers can access annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s operations, risk factors, research and development activities, and financial statements. Current reports on Form 8-K capture material events, including clinical data updates from the Phase 1b study of GT-02287, financial results, changes in corporate governance, amendments to the certificate of incorporation, and other significant corporate actions.
Investors interested in capital structure and corporate actions can review filings that discuss increases in authorized shares of common stock, shareholder meeting results, and other matters submitted to a vote of security holders. These documents help explain how Gain Therapeutics manages its equity base as it advances its clinical and preclinical programs.
For those tracking clinical development disclosures, 8-K filings and related exhibits often summarize preliminary safety and tolerability findings, exploratory biomarker endpoints such as glucosylsphingosine (GluSph) changes in cerebrospinal fluid, and recommendations from independent data monitoring committees. These filings complement the company’s press releases by providing formal regulatory context for key milestones in the GT-02287 program.
Stock Titan enhances access to these documents with AI-powered summaries that highlight important points from lengthy filings, helping readers interpret complex sections without replacing the original text. Real-time updates from the EDGAR system ensure that new 10-K, 10-Q, 8-K and other forms are available as they are filed, while tools for viewing insider-related filings such as Form 4, when present, can assist in monitoring transactions by directors and officers of Gain Therapeutics.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing a routine equity award to director Eric I. Richman. On 06/24/2025 the director received 15,000 stock options with an exercise price of $1.79 per share.
The options vest in 12 equal monthly installments beginning 07/24/2025, contingent on continued board service, and expire on 06/24/2035. Following the grant, Richman beneficially owns 15,000 derivative securities, all held directly. No shares of common stock were bought or sold, and no other transactions were reported.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Hans Peter Hasler received 15,000 stock options on 06/24/2025. The options carry a $1.79 exercise price, expire on 06/24/2035, and will vest in 12 equal monthly tranches beginning 07/24/2025, contingent on continued board service. No common shares were bought or sold; the filing solely reflects an equity-incentive grant. After the transaction, Hasler beneficially owns 15,000 derivative securities, all held directly. The grant is routine board compensation and does not signal any change in the company’s operating outlook, capital structure, or insider sentiment.
Gain Therapeutics, Inc. (GANX) – Director equity award filing.
On 06/24/2025 director Dr. Dov A. Goldstein filed a Form 4 disclosing the receipt of a stock option for 15,000 common shares at an exercise price of $1.79 per share. The option vests in 12 equal monthly installments beginning 07/24/2025, contingent on the director’s continued service, and carries a 10-year term expiring 06/24/2035.
No common shares were bought or sold; the only reportable event is the option grant. After the transaction, Dr. Goldstein holds 15,000 derivative securities, all in direct ownership form. The filing does not reference any Rule 10b5-1 plan, open-market purchase, or disposition, and there is no indication of additional indirect holdings.
The award appears to be routine director compensation designed to align incentives rather than a signal of a major strategic development. The relatively small size versus GANX’s share count limits any dilution or immediate valuation impact, but it modestly increases insider exposure to the company’s equity performance.
Gain Therapeutics, Inc. (GANX) – Form 4 insider filing
Director Gwen A. Melincoff reported the grant of a derivative security in the form of a stock option for 15,000 common shares on 24 June 2025. The option carries an exercise price of $1.79 per share and will expire on 24 June 2035.
Vesting schedule: the option vests in 12 equal monthly instalments beginning 24 July 2025, contingent on the director’s continued service. No sales, exercises, or other dispositions were reported, and the filing shows direct ownership ("D") of the entire option position.
The filing does not list any non-derivative share transactions, cash compensation, or other equity awards. Because Form 4 must be filed within two business days of a reportable event, this document confirms the timely disclosure of the grant.
For investors, the grant represents routine director compensation and involves a limited potential dilution relative to Gain Therapeutics’ outstanding share count. No immediate cash outlay by the insider was required, and there is no indication of open-market buying or selling.
Gain Therapeutics (GANX) held its Annual Meeting on June 24, 2025, where stockholders approved several key proposals. Most significantly, shareholders approved doubling the company's authorized common stock from 50 million to 100 million shares, with 16.3M votes in favor versus 2.2M against.
The meeting also resulted in the following outcomes:
- All eight director nominees were successfully elected to one-year terms, with Gene Mack, Dov Goldstein, and Gwen Melincoff receiving the highest approval rates
- Ernst & Young AG's appointment as independent auditor was ratified with strong support (18M votes in favor)
- A contingency measure for meeting adjournment was approved with 17.9M supporting votes
The company, an emerging growth company listed on Nasdaq, filed the Certificate of Amendment with Delaware's Secretary of State to formally implement the authorized share increase. This expansion of authorized shares could provide additional flexibility for future capital raising or strategic transactions.